VIP

VIP - Vasoactive Intestinal Peptide Research Compound

VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide first isolated from porcine intestine in 1970 by Said and Mutt. It is widely distributed through the central nervous system, gastrointestinal tract, immune cells, and vasculature - which is why it has been studied across neuroimmune, vasodilatory, and anti-inflammatory research axes. In the peptide-research toolkit, VIP is the reference neuropeptide for VPAC1/VPAC2 receptor characterization and for studies of Th1/Th2 cytokine balance.

Why VIP’s Multi-Receptor Profile Matters

VIP binds two G-protein-coupled receptors - VPAC1 and VPAC2 - that are expressed on different tissues. VPAC1 is concentrated on T cells, macrophages, and the intestinal epithelium; VPAC2 is concentrated on smooth muscle and the suprachiasmatic nucleus. That distribution is why a single peptide produces both immune-modulatory and vasodilatory signaling, and why VIP is cited across such a wide range of published research rather than sitting in one category.

Research Applications

VIP is used in studies examining:

• Anti-inflammatory signaling and Th1/Th2 cytokine balance
• VPAC1 and VPAC2 receptor characterization
• Vasodilation and smooth-muscle relaxation models
• Experimental arthritis and autoimmune-inflammation research
• Circadian signaling via suprachiasmatic nucleus endpoints
• CIRS (chronic inflammatory response syndrome) research literature

Specifications

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for VIP are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical VIP literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About VIP Research

What is VIP peptide used for in research?

It is most commonly studied as a neuroimmune modulator. Published work covers anti-inflammatory signaling, Th1/Th2 cytokine balance, vasodilation, experimental arthritis models, and circadian signaling. It does not sit in a single category - VIP is cited across immune, vascular, and neuroscience literature.

What does VIP do in research models?

It binds two G-protein-coupled receptors (VPAC1 and VPAC2). VPAC1 activation modulates T-cell and macrophage cytokine release; VPAC2 activation produces smooth-muscle relaxation and vasodilation. The downstream effects cited in the literature include reduced pro-inflammatory cytokine output, vasodilation, and Th1/Th2 ratio shifts.

What is the difference between VIP and PACAP?

PACAP (pituitary adenylate cyclase-activating peptide) is VIP’s closest structural relative and shares the VPAC1 and VPAC2 receptors. PACAP also binds a third receptor (PAC1) with higher affinity than VIP. The two peptides are often studied together in neuroimmune research.

Is VIP FDA approved?

No. Vasoactive Intestinal Peptide is not FDA approved for any use. It is studied as a research compound only. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is VIP stored?

Unopened vials are stored at 2-8°C and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.